JP2022506958A5 - - Google Patents

Info

Publication number
JP2022506958A5
JP2022506958A5 JP2021525119A JP2021525119A JP2022506958A5 JP 2022506958 A5 JP2022506958 A5 JP 2022506958A5 JP 2021525119 A JP2021525119 A JP 2021525119A JP 2021525119 A JP2021525119 A JP 2021525119A JP 2022506958 A5 JP2022506958 A5 JP 2022506958A5
Authority
JP
Japan
Prior art keywords
nucleoside
composition according
compound
subscript
modified oligonucleotide
Prior art date
Application number
JP2021525119A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020102142A5 (https=
JP2022506958A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/060841 external-priority patent/WO2020102142A1/en
Publication of JP2022506958A publication Critical patent/JP2022506958A/ja
Publication of JPWO2020102142A5 publication Critical patent/JPWO2020102142A5/ja
Publication of JP2022506958A5 publication Critical patent/JP2022506958A5/ja
Pending legal-status Critical Current

Links

JP2021525119A 2018-11-13 2019-11-12 Mir-10b活性を調節するためのマイクロrna化合物及び方法 Pending JP2022506958A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862760546P 2018-11-13 2018-11-13
US62/760,546 2018-11-13
PCT/US2019/060841 WO2020102142A1 (en) 2018-11-13 2019-11-12 Microrna compounds and methods for modulating mir-10b activity

Publications (3)

Publication Number Publication Date
JP2022506958A JP2022506958A (ja) 2022-01-17
JPWO2020102142A5 JPWO2020102142A5 (https=) 2022-10-03
JP2022506958A5 true JP2022506958A5 (https=) 2022-10-03

Family

ID=68808539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021525119A Pending JP2022506958A (ja) 2018-11-13 2019-11-12 Mir-10b活性を調節するためのマイクロrna化合物及び方法

Country Status (10)

Country Link
US (1) US20220096517A1 (https=)
EP (1) EP3880310A1 (https=)
JP (1) JP2022506958A (https=)
KR (1) KR20210091732A (https=)
CN (1) CN112996568A (https=)
AU (1) AU2019381681A1 (https=)
CA (1) CA3117981A1 (https=)
MA (1) MA54226A (https=)
TW (1) TW202031268A (https=)
WO (1) WO2020102142A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3192788A1 (en) 2006-10-03 2017-07-19 Arbutus Biopharma Corporation Lipid containing formulations
CN102186998A (zh) * 2008-08-19 2011-09-14 人类遗传学与健康缅因州研究院 微小rna和1型神经纤维瘤病在诊断和治疗中
ES2555057T3 (es) * 2009-06-12 2015-12-28 Roche Innovation Center Copenhagen A/S Nuevos potentes compuestos antisentido anti-ApoB
EP2490699A1 (en) * 2009-10-20 2012-08-29 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
EP2753692B1 (en) * 2011-09-07 2019-03-27 3-D Matrix Ltd. Microrna-based methods and assays for osteosarcoma
PE20142404A1 (es) * 2012-04-25 2015-02-02 Regulus Therapeutics Inc Compuestos de microarn y metodos de modulacion de la actividad de mir-21
IL322679A (en) * 2016-12-05 2025-10-01 Regulus Therapeutics Inc Modified oligonucleotides for the treatment of polycystic kidney disease

Similar Documents

Publication Publication Date Title
Messaoudi et al. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide
JP7498230B2 (ja) 5-ハロウラシル修飾マイクロrna及びがんの処置におけるその使用
US9200285B2 (en) Clusterin antisense therapy for treatment of cancer
JP7558963B2 (ja) 修飾されたマイクロrna及びがんの処置におけるその使用
US12371693B2 (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
JP2022506958A5 (https=)
US11236337B2 (en) 5-halouracil-modified microRNAs and their use in the treatment of cancer
KR101843985B1 (ko) 암을 치료하기 위한 조성물과 방법
JP2011515357A5 (https=)
TW201038278A (en) Rnai molecule for thymidylate synthase and use thereof
US12319913B2 (en) 5-halouracil-modified microRNAs and their use in the treatment of cancer
KR101843984B1 (ko) 췌장암을 치료하기 위한 조성물과 방법
US20080274121A1 (en) Inhibition of Angiogenesis by Mithramycin
JPWO2020102142A5 (https=)
Leighl et al. A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium
JP2007525414A (ja) スラミン、ペントサン・ポリサルフェート、テロメラーゼアンチセンス、及びテロメラーゼ阻害剤を用いるための方法及び成分
JP7707184B2 (ja) 修飾短干渉rna組成物、及びがんの処置におけるそれらの使用
US20130296407A1 (en) Combination Therapy for Cancer
US20250327075A1 (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
JP7498448B2 (ja) SNHG12遺伝子に由来するncRNAの発現抑制剤を有効成分とするがん増殖抑制剤
US20070270371A1 (en) Dosing and scheduling of oligomers
TH1901003361A (th) โอลิโกนิวคลีโอไทด์ที่ถูกดัดแปลงสำหรับการบำบัดโรคถุงน้ำในไต